Advertisement

Adult Immunization

 
Recombinant Zoster Vaccine Protection Durable at 10 Years, New Study Finds
October 25, 2022

Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.

High-dose Influenza Vaccine Consistently More Effective vs Standard-dose in Older Adults: Meta-analysis
October 24, 2022

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

US FDA Grants EUA for Novavax COVID-19 Booster Shot
October 20, 2022

Another choice of booster may help increase follow-up vaccination among the 50% of US adults who have yet to get a first booster dose.

How to Talk to Patients about Coadministration of Influenza and COVID-19 Vaccines This Year
October 19, 2022

AAFP Board Chair Sterling Ransone, Jr, MD, encourages patients to get both shots at one visit; if they don't, he has strategies to bring them back for the one they didn't get.

AAFP Tips on Getting Shots into Arms this Flu Season with Sterling Ransone, Jr, MD
October 18, 2022

AAFP Board Chair Sterling Ransone, Jr, MD, offers an Academy refresher on the annual push-back from patients that is so familiar to family medicine clinicians.

GSK Announces Positive Pivotal Phase 3 Data for Adult RSV Vaccine Candidate
October 14, 2022

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

Americans Have not Been Truthful about Following COVID-19 Precautions
October 10, 2022

More than 4 in 10 US adults have either misrepresented their COVID-19 status or failed to adhere to public health measures. A new survey found out why.

Phase 3 Trial Now Underway of Investigational mRNA-based Influenza Vaccine
September 20, 2022

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.

COVID-19 mRNA Vaccines Found Safe in Patients with Heart Failure in Real-world Study
September 07, 2022

ESC 2022: SARS-CoV-2 mRNA vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism, or myocarditis in a large Danish real-world study.

Pfizer Reports Positive Topline Phase 3 Data for Bivalent RSV Vaccine in Older Adults
August 26, 2022

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.

Advertisement
Advertisement